Puma Biotechnology Inc - Common Stock (NQ:PBYI)

10.44 -0.10 (-0.95%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

February 27, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference

February 22, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024

From Puma Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

February 14, 2024

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

February 13, 2024

From Puma Biotechnology, Inc.

Via Business Wire

3 small-cap biotechs with potential breakthroughs in 2024

February 06, 2024

These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024.

Via MarketBeat

Topics Bankruptcy

3 Strong Buy Stocks Under $5: January 2024 ↗

January 31, 2024

A strong buy rating carries weight which speculative investors may want to research in these strong buy stocks under $5.

Via InvestorPlace

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

January 11, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

December 11, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

November 06, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Third Quarter 2023 Financial Results

November 02, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

October 19, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

October 14, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

October 04, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

September 21, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 31, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

August 08, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Second Quarter Financial Results

August 03, 2023

From Puma Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 24, 2023

Via Benzinga

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

July 20, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Why Nanobiotix Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗

July 20, 2023

Gainers Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares surged 39.3% to $0.6621 in pre-market trading after gaining around 14% on Wednesday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

July 20, 2023

It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Thursday morning!

Via InvestorPlace

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

June 04, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2023

From Puma Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 05, 2023

Via Benzinga

Puma Biotechnology Reports First Quarter Financial Results

May 04, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

April 20, 2023

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

April 11, 2023

From Puma Biotechnology, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.